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Introduction {#sec005}
============

Chronic kidney disease (CKD) is a growing public health problem. According to the Global Burden of Disease Study 2016, more than 200 million people worldwide have CKD \[[@pone.0238111.ref001]\]. In addition, in the United States, the number of patients with end-stage renal disease (ESRD) who require renal replacement therapy (RRT) is more than 400,000 \[[@pone.0238111.ref002]\]. Many studies identified risk factors, such as advanced age, hypertension, diabetes mellitus (DM), dyslipidemia, obesity, and usage of nephrotoxic agents, for CKD \[[@pone.0238111.ref003]--[@pone.0238111.ref009]\], Because CKD is accompanied by concomitant disease burden, increased mortality, and high healthcare cost, management of the modifiable risk factors should be the key strategy for prevention of CKD.

Cigarette smoking is a leading cause for preventable death from cardiovascular disease (CVD) and cancer \[[@pone.0238111.ref010]\]. Although controversial, several studies have shown that the risk of incident CVD decreases with increase in the smoking cessation period \[[@pone.0238111.ref011]--[@pone.0238111.ref014]\]. In addition, smoking cessation at an earlier age is associated with lower risk of death \[[@pone.0238111.ref015], [@pone.0238111.ref016]\]. Therefore, cigarette smoking is considered an important modifiable risk factor, and smoking cessation has become a major target policy for many countries. Smoking promotes atherosclerosis and vascular dysfunction; hence, it can cause damage to other organs, including the kidney. In fact, many epidemiologic studies to date have demonstrated the negative impacts of smoking on kidney health \[[@pone.0238111.ref017]--[@pone.0238111.ref025]\]. Although there have been several observational studies that determined the effects of smoking exposure on kidney function, assessments comparing the risk of kidney damage with those who stopped smoking after active smoking periods have been limited. In addition, the duration of most previous reports was relatively short and could not evaluate the long-term effects of smoking on kidney function. \[[@pone.0238111.ref020], [@pone.0238111.ref026]--[@pone.0238111.ref028]\].

In this study, we sought to clarify the long-term relationship between smoking and kidney function in healthy middle-aged Korean adults. In addition, we examined whether smoking cessation can help prevent kidney disease.

Materials and methods {#sec006}
=====================

Study design and subjects {#sec007}
-------------------------

The Korean Genome and Epidemiology Study (KoGES) is a population-based cohort study conducted in rural (Ansung) and urban (Ansan) areas of South Korea. This study was designed to elucidate the interaction between lifestyle factors and genetic risk factors in the development of non-communicable diseases, including CKD. The detailed profile and methods on construction of the KoGES cohort are described elsewhere \[[@pone.0238111.ref029]\]. Briefly, 10,030 participants were enrolled between 2001 and 2002. Biannual health examinations and surveys were provided to the participants until 2014, and the retention rate was 62.8% at the end of the 6^th^ follow-up phase. We excluded (a) patients with estimated glomerular filtrating rate (eGFR) \<60 mL/min/1.73 m^2^, (b) those with urine dipstick positive proteinuria ≥ 1+ at baseline, (c) those with missing follow-up data for serum creatinine level or urinary dipstick test, and (d) those without available information for smoking status ([Fig 1](#pone.0238111.g001){ref-type="fig"}). Thus, 8,661 participants were included in the final analysis. All participants provided informed consent. The present study was carried out in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Yonsei University Health System Clinical Trial Center (4-2016-0100).

![Flow diagram of the study cohort.\
*Abbreviation*: eGFR, estimated glomerular filtration rate.](pone.0238111.g001){#pone.0238111.g001}

Data measurement {#sec008}
----------------

Demographic and socioeconomic data, including age, sex, medical history, education and income levels, smoking status, and alcohol intake were obtained using a standardized self-administered questionnaire at enrollment. Patients with a history of alcohol intake were categorized as non- or current drinkers. Blood pressure was measured by trained nurses using a standard mercury sphygmomanometer with the subject in the sitting position after a 5-min rest. Blood and urine samples were obtained after an 8-h fast and transported to a central laboratory (Seoul Clinical Laboratories, Seoul, Republic of Korea) within 24 hours of sampling. Serum concentrations of blood urea nitrogen, creatinine, albumin, glucose, total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol (LDL-C), and C-reactive protein (CRP) were measured. Urine samples were collected in the morning after the first voiding and were subjected to a dipstick test (URISCAN Pro II; YD Diagnostics Corp., Seoul, Korea). The presence of proteinuria was defined as protein level 1+ in the dipstick urine test. The eGFR was calculated using the CKD epidemiology collaboration equation.

Exposure and study outcome {#sec009}
--------------------------

The primary exposure of interest was smoking status, and the subjects were classified as non-, former-, and current-smokers. Data for age at initiation of smoking, number of years smoked, and average number of packs of cigarettes smoked per day were also collected from the former- and current-smokers. The smoking pack-years were calculated as the number of years smoked × the average number of packs of cigarettes smoked per day. The surveys collected at enrollment and the second visit were used to assess baseline smoking status.

The primary outcome was incident CKD, which was defined as the occurrence of eGFR \<60 ml/min/1.73 m^2^ or newly developed proteinuria (defined as urine dipstick protein≥1+). The study observation ended on December 31, 2014.

Statistical analysis {#sec010}
--------------------

All statistical analyses were performed using STATA version 15.1 (StataCorp, College Station, TX, USA). For missing data imputation, the MICE (multivariate imputation by chained equations) method of multiple multivariate imputation in STATA was used. The missing data analysis procedures used missing at random assumptions ([S1 Table](#pone.0238111.s001){ref-type="supplementary-material"}). We independently analyzed 5 copies of the data, each with missing values suitably imputed, in the multivariable cox regression analyses. The estimates of the variables were averaged to give a single mean estimate and standard errors were adjusted according to Rubin's rules \[[@pone.0238111.ref030]\]. The continuous variables were expressed as mean ± standard deviation or median and interquartile ranges, while the categorical variables were expressed as frequencies with percentages. All data were tested for normality before statistical analysis. The Kolmogorov-Smirnov test was performed to determine the normality of distribution of the parameters. Comparisons between groups were performed using analysis of variance with a normal distribution, and the chi-square test or Fisher's exact test was used for analysis of the categorical variables. Data that did not show a normal distribution were compared using the Kruskal-Wallis test. Cumulative renal survival rates were estimated by Kaplan-Meier analysis and a log-rank test. Multivariable Cox proportional hazard models with a 3-step adjustment level were constructed to determine the independent association of smoking status with incident CKD. The proportionality assumptions for the cause-specific models were tested through inspection of log (-log \[survival\]) curves, and no violations were observed. Multivariable models were constructed with adjustment for confounding factors. Variables that showed statistical significance in univariable regression analyses were selected for the multivariable model. Model 1 was adjusted for age and sex. Model 2 was further adjusted for comorbidities and socioeconomic factors such as, hypertension, DM, alcohol status, education, income level, and BMI. Model 3 was fully adjusted for the above factors plus laboratory results including albumin and total cholesterol level. The results of the Cox models were presented as HR and 95% confidence interval (CI). Patients who were lost to follow-up or death were censored at the date of the last examination. To test the dose-response relationship between smoking load and incident CKD, we repeated the same Cox analysis after the smokers were classified by 15-year increment in pack-years of smoking. We also performed the subgroup analyses across the following subgroups: age (\<60 and ≥60 years), sex, hypertension, DM, body mass index (BMI) (\<25 and ≥25 kg/m^2^), alcohol status, and income and education levels. In addition, the association between smoking cessation and risk of the adverse kidney outcome among former-smokers classified by 10-year increments of cessation duration was assessed. For subgroup analysis, the interaction terms between each stratifying factor and smoking status on incident CKD was assessed in adjusted cause-specific proportional hazard models using the likelihood ratio test. Adjustments were made with the fully adjusted model 3 of the multivariable Cox proportional hazard models. Linear mixed-effect models of annual eGFR decline according to smoking status and timed updated smoking status were constructed with adjustment of confounding factors. For all analyses, *p*\<0.05 was considered statistically significant.

Results {#sec011}
=======

Baseline characteristics {#sec012}
------------------------

The baseline characteristics by smoking status are shown in [Table 1](#pone.0238111.t001){ref-type="table"}. The mean age of the study cohort was 52 years and 47.6% were men. There were 551 (6.4%) subjects with diabetes and 1,255 (14.5%) with hypertension. The mean eGFR was 93.0 ml/min/1.73 m^2^. Among the participants, 5,140 (59.3%), 1,336 (15.4%), and 2,185 (25.2%) were never-smokers, former-smokers, and current-smokers, respectively. There were more patients with diabetes but fewer patients with hypertension among smokers than among never smokers. Smokers consumed more alcohol and had higher levels of education and income than non-smokers. Baseline kidney function was slightly better in non-smokers than in smokers.

10.1371/journal.pone.0238111.t001

###### Baseline characteristics of participants according to smoking status.

![](pone.0238111.t001){#pone.0238111.t001g}

  Variables                                                        Total                 Never smokers         Smokers                                     
  ---------------------------------------------------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
  **Smoking**                                                                                                                                              
   Smoking period (years)                                          10.0±14.1                                   24.5±11.4             20.1±11.4             27.2±10.5
   Smoking load (pack-year)                                        9.5±15.9                                    23.3±17.2             21.0±18.6             24.8±16.2
  **Age (years)**                                                  52.1±8.8              52.3±8.8              51.7±8.8              52.4±9.0              51.3±8.7
  **Male**, **n (%)**                                              4,124 (47.6)          818 (15.9)            3,306 (93.9)          1,283 (96.0)          2,023 (92.6)
  **Body mass index (kg/m**^**2**^**)**                            24.6±3.2              24.8±3.2              24.2±3.0              24.5±2.8              23.9±3.1
  **Systolic BP (mmHg)**                                           121.3±18.2            121.3±19.0            121.2±17.1            123.1±17.3            120.1±16.8
  **Diastolic BP (mmHg)**                                          80.2±11.4             79.5±11.6             81.3±10.9             82.5±11.0             80.5±10.7
  **Comorbidities**, **n (%)**                                                                                                                             
   Hypertension                                                    1,255 (14.5)          810 (15.8)            445 (12.6)            217 (16.2)            228 (10.4)
   Diabetes                                                        551 (6.4)             294 (5.7)             257 (7.3)             111 (8.3)             146 (6.7)
   Cardiovascular disease                                          63 (0.7)              39 (0.8)              24 (0.7)              15 (1.1)              9 (0.4)
  **Alcohol**, **n (%)**                                           4,096 (47.3)          1,548 (30.1)          2,548 (72.4)          903 (67.6)            1,645 (75.3)
  **Education**[^b^](#t001fn002){ref-type="table-fn"}, **n (%)**                                                                                           
   Low                                                             2,857 (33.0)          2,087 (40.6)          770 (21.9)            264 (19.8)            506 (23.2)
   Middle                                                          4,590 (53.0)          2,567 (49.9)          2,023 (57.5)          760 (56.9)            1,263 (57.8)
   High                                                            1,214 (14.0)          486 (9.5)             774 (20.7)            312 (23.4)            416 (19.0)
  **Income**[^c^](#t001fn003){ref-type="table-fn"}, **n (%)**                                                                                              
   Low                                                             2,991 (34.5)          1,967 (38.3)          1,024 (29.1)          342 (25.6)            682 (31.2)
   Middle                                                          4,036 (46.6)          2,313 (45.0)          1,723 (48.9)          666 (49.9)            1,057 (48.4)
   High                                                            1,634 (18.9)          860 (16.7)            774 (22.0)            328 (24.6)            446 (20.4)
  **Laboratory findings**                                                                                                                                  
   WBC count (10^3^/μL)                                            6.5±1.8               6.3±1.7               6.9±1.9               6.4±1.6               7.2±1.9
   Hemoglobin (g/dL)                                               13.6±1.6              12.9±1.4              14.6±1.2              14.6±1.2              14.7±1.2
   Albumin (g/dL)                                                  4.2±0.3               4.2±0.3               4.3±0.4               4.4±0.4               4.3±0.3
   eGFR (mL/min/1.73m^2^)                                          93.0±13.0             93.7±12.8             91.9±13.3             90.2±13.4             92.9±13.1
   Total cholesterol (mg/dL)                                       190.6±35.0            190.0±34.4            191.3±35.9            194.0±35.5            189.7±36.1
   LDL-cholesterol (mg/dL)                                         113.7±33.1            114.8±31.5            112.2±35.2            115.5±34.6            110.1±35.4
   HDL-cholesterol (mg/dL)                                         44.7±10.0             45.3±9.9              43.7±10.0             43.9±9.6              43.6±10.2
   Triglyceride^a^ (mg/dL)                                         135 \[99, 189\]       127 \[95, 176\]       148 \[110, 210\]      146 \[108, 200\]      149 \[110, 217\]
   CRP^a^ (mg/dL)                                                  0.14 \[0.07, 0.25\]   0.14 \[0.07, 0.24\]   0.15 \[0.07, 0.26\]   0.14 \[0.07, 0.26\]   0.15 \[0.07, 0.26\]

All data are expressed as mean ± SD or ^a^ median (and interquartile range).

^b^ Low, primary education; middle, secondary education; and high, tertiary education.

^c^ Low, \<1,000,000; ≥1,000,000 and \<3,000,000; and high, ≥3,000,000 won per month.

***Abbreviations***: BP, blood pressure; WBC, white blood cell; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein, and CRP, high-sensitivity C-reactive protein.

Risk of the incident CKD according smoking status {#sec013}
-------------------------------------------------

During a median follow-up of 11.6 years, incident CKD developed in 1,941 (22.4%) subjects with a crude incidence rate of 25.1 (24.0--26.2) per 1,000 person-years. Poisson regression after adjustment of confounding factors showed that the incidence rate ratio (IRR) of incident CKD was highest in the current smoking group ([Fig 2](#pone.0238111.g002){ref-type="fig"}). IRRs (95% confidence interval) were 1.11 (0.94--1.33) and 1.19 (1.01--1.39) in the former smokers and current smokers, compared with never smokers. The Kaplan-Meier plots showed that the time to the development of incident CKD was significantly longer in never smokers than current smokers or former smokers ([Fig 3](#pone.0238111.g003){ref-type="fig"}). The multivariable Cox regression analysis after adjustment of confounding factors showed hazard ratios (95% CI) of 1.13 (0.95--1.35) and 1.26 (1.07--1.48) for CKD development in the former- and current-smokers, compared with never-smokers ([Table 2](#pone.0238111.t002){ref-type="table"}). Additionally, linear mixed-effects models were constructed, using repeated eGFR measurements of each participant, to evaluate the effect of smoking status on the decline slope of eGFR. The annual eGFR decline was more rapid among current smokers (-1.569 mL/min/1.73m^2^/year) compared to never smokers (-1.282 mL/min/1.73m^2^/year, *p*\<0.001) or former smokers (-1.274 mL/min/1.73m^2^/year, *p*\<0.001) ([S2 Table](#pone.0238111.s002){ref-type="supplementary-material"}). A similar relationship between smoking status and annual eGFR decline was also found when smoking status was treated as a time dependent variable ([S3 Table](#pone.0238111.s003){ref-type="supplementary-material"}).

![Adjusted incidence rate ratio of CKD according to smoking status.\
*Abbreviation*: IRR, incidence rate ratio.](pone.0238111.g002){#pone.0238111.g002}

![Kaplan-Meier curve for incident CKD.](pone.0238111.g003){#pone.0238111.g003}

10.1371/journal.pone.0238111.t002

###### Hazard ratios for incident CKD by smoking status.
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                        Model 1             Model 2     Model 3                                         
  --------------------- ------------------- ----------- ------------------- ------- ------------------- -------
  **Never smokers**     Reference           Reference   Reference                                       
  **Former smokers**    1.14 (0.95--1.35)   0.140       1.13 (0.95--1.35)   0.174   1.13 (0.95--1.35)   0.164
  **Current smokers**   1.15 (0.99--1.35)   0.075       1.25 (1.07--1.47)   0.006   1.26 (1.07--1.48)   0.005

**Model 1**: Adjusted for age and sex.

**Model 2**: Model 1 + HTN, DM, alcohol, education, income, and BMI.

**Model 3**: Model 2 + Albumin and total cholesterol.

***Abbreviations***: HR, hazard ratio; CI, confidence interval; eGFR, estimated glomerular filtration; HTN, hypertension; DM, diabetes mellitus; BMI, body mass index.

Dose-dependent relationship between smoking load and incident CKD {#sec014}
-----------------------------------------------------------------

Next, we analyzed the association between smoking load and incident CKD. Smokers were classified into 3 groups by pack-years of smoking (15-year increments). The HRs (95% CIs) were 1.14 (0.94--1.37), 1.07 (0.85--1.34), and 1.12 (0.93--1.36) for- \<15, 15--29, and ≥30 pack-years of smoking, respectively, as compared to never-smokers ([Table 3](#pone.0238111.t003){ref-type="table"}). However, the differences were not statistically significant.

10.1371/journal.pone.0238111.t003

###### Hazard ratios for incident CKD according to smoking load.
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                        Model 1             Model 2     Model 3                                         
  --------------------- ------------------- ----------- ------------------- ------- ------------------- -------
  **Never smokers**     Reference           Reference   Reference                                       
  **Smoking load**                                                                                      
   0--15 pack x year    1.11 (0.94--1.32)   0.222       1.16 (0.97--1.38)   0.101   1.14 (0.94--1.37)   0.187
   15--30 pack x year   1.04 (0.85--1.28)   0.683       1.12 (0.91--1.38)   0.277   1.07 (0.85--1.34)   0.567
   \>30 pack x year     1.14 (0.95--1.36)   0.150       1.19 (1.00--1.42)   0.054   1.12 (0.93--1.36)   0.229

**Model 1**: Adjusted for age and sex.

**Model 2**: Model 1 + HTN, DM, alcohol, education, income, and BMI.

**Model 3**: Model 2 + Albumin and total cholesterol.

***Abbreviations***: HR, hazard ratio; CI, confidence interval; eGFR, estimated glomerular filtration; HTN, hypertension; DM, diabetes mellitus; BMI, body mass index.

Subgroup analysis {#sec015}
-----------------

Further examinations were done to evaluate the association between smoking and kidney outcome in subgroups stratified by sex, age (\<60 or ≥60 years), presence of hypertension and diabetes, BMI (\<25 or ≥25 kg/m^2^), alcohol status, and income and educational levels. When the interaction terms between each stratifying factor and the effect of current-smoking on incident CKD was assessed, no significant interactions were found in any of the subgroups. This suggests that the increased incident CKD risk in current smokers compared to never smokers were consistently significant across these subgroups ([S4 Table](#pone.0238111.s004){ref-type="supplementary-material"}).

Smoking cessation and risk of incident CKD {#sec016}
------------------------------------------

Finally, to assess whether smoking cessation can aid in preventing CKD development, we subdivided the former smokers into three groups by cessation duration in 10-year increments. After adjusting for the confounding factors, smoking cessation for 20 years and more showed relationship with lower risk of incident CKD (HR, 0.76; 95% CI, 0.62--0.94), while quitting smoking for less than 20 years was not ([Table 4](#pone.0238111.t004){ref-type="table"}).

10.1371/journal.pone.0238111.t004

###### Hazard ratios for incident CKD according to duration of smoking cessation.
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                           Model 1             Model 2     Model 3                                         
  ------------------------ ------------------- ----------- ------------------- ------- ------------------- -------
  **Current smokers**      Reference           Reference   Reference                                       
  **Cessation duration**                                                                                   
   0--10 years             0.81 (0.61--1.07)   0.145       0.77 (0.58--1.01)   0.063   0.83 (0.63--1.09)   0.181
   10--20 years            0.88 (0.68--1.16)   0.369       0.84 (0.64--1.10)   0.194   0.89 (0.68--1.17)   0.414
   \>20 years              0.78 (0.63--0.96)   0.021       0.77 (0.62--0.95)   0.014   0.76 (0.62--0.94)   0.012

**Model 1**: Adjusted for age and sex.

**Model 2**: Model 1 + HTN, DM, alcohol, education, income, and BMI.

**Model 3**: Model 2 + Albumin and total cholesterol.

***Abbreviations***: HR, hazard ratio; CI, confidence interval; eGFR, estimated glomerular filtration; HTN, hypertension; DM, diabetes mellitus; BMI, body mass index.

Discussion {#sec017}
==========

In this population-based cohort study with a median follow-up of 11.6 years, we found that current smoking was associated with a higher risk of CKD development in middle-aged people without kidney disease. In addition, among former smokers, smoking cessation for ≥ 20 years was associated with a lower risk of incident CKD, suggesting that quitting smoking may be helpful in preventing the development of CKD.

Our findings add evidence to the prevailing notion that smoking is harmful for vascular health. Regarding kidney disease, previous studies have shown that smoking is associated with the presence of proteinuria and impaired kidney function \[[@pone.0238111.ref021]--[@pone.0238111.ref023], [@pone.0238111.ref026], [@pone.0238111.ref027], [@pone.0238111.ref031], [@pone.0238111.ref032]\]. However, our study was different in several aspects. Many previous studies were cross-sectional or retrospective observations \[[@pone.0238111.ref021], [@pone.0238111.ref023], [@pone.0238111.ref031], [@pone.0238111.ref032]\], did not have follow-up measures for kidney function \[[@pone.0238111.ref022]\], and defined the study outcome as ESRD \[[@pone.0238111.ref026], [@pone.0238111.ref027]\]. The strengths of the present study lie in the analyses with well-organized longitudinal data from a prospective cohort, long-term observation, and rigorous adjustment of many confounding factors. Because people in our cohort had normal kidney function and few comorbid conditions at study entry, more severe kidney outcomes such as ESRD rarely occurred during follow-up. However, our longitudinal long-term observation over a 11-year duration enabled us to detect early CKD development in healthy middle-aged people without kidney disease. Thus, our findings, along with those of previous studies, confirm the harmful impact of smoking on kidney health in people who do not have overt kidney disease.

To date, few studies have addressed whether smoking is a modifiable factor for the prevention of kidney disease. However, this can be inferred from previous studies in the field of cardiovascular disease research. In a collective analysis using the Cochrane database, quitting smoking was associated with 36% and 32% lower risk of mortality and non-fatal myocardial infarctions, respectively, among patients with coronary heart disease \[[@pone.0238111.ref033]\]. Accordingly, all guidelines recommend quitting smoking as a first-line measure for the prevention of cardiovascular disease based on many epidemiologic studies \[[@pone.0238111.ref011], [@pone.0238111.ref034]--[@pone.0238111.ref036]\]. The effect of smoking cessation on kidney failure has recently been studied in two large cohorts \[[@pone.0238111.ref026], [@pone.0238111.ref037]\]. Both studies conducted using the Singapore Chinese and Norwegian cohorts showed that the risk of kidney failure, defined as progression to CKD stage 5 or the initiation of dialysis treatment, was lower in people with prolonged smoking cessation. In agreement with these studies, we showed that early smoking cessation was associated with a lower risk of CKD development among former smokers. However, the time elapsed to observe the beneficial effects of smoking cessation appears to be longer because the statistical significance was observed in those who had quit smoking for ≥ 20 years. Presumably, the adverse effects of smoking on the kidney should be taken into account in light of other cardiovascular system disorders, and its cumulative residual effects may last longer than expected even after quitting smoking. Taken together, our findings are informative for establishing a preventive strategy against the development of kidney disease from the viewpoint of public health.

Our study has several limitations. First, this observational study cannot entirely eliminate confounding, although we rigorously adjusted potential factors that might affect clinical outcomes. In addition, causality between smoking exposure and incident CKD is uncertain. However, conducting randomized controlled trials on this issue appear to be infeasible for ethical reasons. Therefore, collecting more evidence regarding the harmful effects of smoking on kidney disease with well-constructed epidemiologic data would be meaningful. Second, information on smoking status relied on a self-reported questionnaire, which might result in inaccurate classification of smokers. Third, in contrast to other western countries \[[@pone.0238111.ref038], [@pone.0238111.ref039]\], only 6.1% of the smokers were women, which is consistent with the Korean national health and nutrition examination survey \[[@pone.0238111.ref040]\]. The unequal distribution of smokers between men and women may be similar in other Asian countries as reported in different cohort studies \[[@pone.0238111.ref026], [@pone.0238111.ref032]\]. This smaller proportion of women smokers did not allow us to analyze whether smoking effects differ between men and women. Fourth, in this study, the magnitude of HR for CKD development was relatively lower than that in another European cohort study \[[@pone.0238111.ref027]\], but similar to that in a Singapore-Chinese cohort study \[[@pone.0238111.ref026]\]. It is unknown whether there is an ethnic difference in kidney injury due to smoking exposure. It should be noted that our cohort comprised healthy adults with few comorbidities. Thus, a 31% higher risk for CKD development in this group may be substantial. In addition, the confidence interval was relatively narrow, suggesting the higher accuracy of this analysis. Finally, the inclusion of only Korean people may limit the generalizability of our findings.

In conclusion, this study showed that cigarette smoking was associated with a higher risk of CKD development in middle-aged healthy adults without kidney disease. Conversely, smoking cessation might be associated with a lower risk of incident CKD among former-smokers. These findings provide robust evidence regarding the harmful effects of smoking on kidney health and highlight the importance of smoking cessation in preventing kidney disease in clinical practice.
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